RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Acer Therapeutics Stock

Acer Therapeutics Revenue 2024

Acer Therapeutics Revenue

49.4 M USD

Ticker

ACER

ISIN

US00444P1084

WKN

A2DYQV

In 2024, Acer Therapeutics's sales reached 49.4 M USD, a 458.59% difference from the 8.84 M USD sales recorded in the previous year.

The Acer Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2028e188.610,67
2027e173.650,73
2026e150.890,84
2025e112.141,12
2024e49.42,55
2023e8.8414,25
2022--
20211.26100,00
2020--
2019--
2018--
2017--
20162.9143,30
20152.5649,22
20141.2799,21
20131.2799,21
2012--
2011--
2010--
2009--
2008--
2007--
2006--
2005--
2004--
2003--

Acer Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Acer Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Acer Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Acer Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Acer Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Acer Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Acer Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Acer Therapeutics’s growth potential.

Acer Therapeutics Revenue, EBIT and net profit per share

DateAcer Therapeutics RevenueAcer Therapeutics EBITAcer Therapeutics Net Income
2028e188.61 M undefined136.5 M undefined0 undefined
2027e173.65 M undefined124.16 M undefined0 undefined
2026e150.89 M undefined104.75 M undefined7.4 M undefined
2025e112.14 M undefined70.62 M undefined18.71 M undefined
2024e49.4 M undefined16.36 M undefined2.99 M undefined
2023e8.84 M undefined-15.09 M undefined-18.09 M undefined
20220 undefined-24.61 M undefined-26.24 M undefined
20211.26 M undefined-15.95 M undefined-15.37 M undefined
20200 undefined-22.8 M undefined-22.89 M undefined
20190 undefined-29.9 M undefined-29.42 M undefined
20180 undefined-21.71 M undefined-21.28 M undefined
20170 undefined-13.95 M undefined-14.19 M undefined
20162.91 M undefined-6.95 M undefined-7.98 M undefined
20152.56 M undefined-12.09 M undefined-12.02 M undefined
20141.27 M undefined-15.07 M undefined-15.05 M undefined
20131.27 M undefined-11.92 M undefined-16.66 M undefined
20120 undefined-9.13 M undefined-8.93 M undefined
20110 undefined-5.96 M undefined-5.97 M undefined
20100 undefined-4.97 M undefined-5.47 M undefined
20090 undefined-4.35 M undefined-1.43 M undefined
20080 undefined-11.97 M undefined-11.85 M undefined
20070 undefined-16.72 M undefined-14.67 M undefined
20060 undefined-13.49 M undefined-12.65 M undefined
20050 undefined-11.52 M undefined-14.86 M undefined
20040 undefined-3.3 M undefined-4.62 M undefined
20030 undefined-80,000 undefined-130,000 undefined

Acer Therapeutics stock margins

The Acer Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Acer Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Acer Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Acer Therapeutics's sales revenue. A higher gross margin percentage indicates that the Acer Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Acer Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Acer Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Acer Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Acer Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Acer Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Acer Therapeutics Margin History

Acer Therapeutics Gross marginAcer Therapeutics Profit marginAcer Therapeutics EBIT marginAcer Therapeutics Profit margin
2028e100 %72.37 %0 %
2027e100 %71.5 %0 %
2026e100 %69.42 %4.9 %
2025e100 %62.97 %16.69 %
2024e100 %33.12 %6.06 %
2023e100 %-170.64 %-204.52 %
2022100 %0 %0 %
2021100 %-1,265.75 %-1,220.16 %
2020100 %0 %0 %
2019100 %0 %0 %
2018100 %0 %0 %
2017100 %0 %0 %
2016100 %-238.83 %-274.23 %
2015100 %-472.27 %-469.53 %
2014100 %-1,186.61 %-1,185.04 %
2013100 %-938.58 %-1,311.81 %
2012100 %0 %0 %
2011100 %0 %0 %
2010100 %0 %0 %
2009100 %0 %0 %
2008100 %0 %0 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %0 %0 %
2004100 %0 %0 %
2003100 %0 %0 %

Acer Therapeutics Aktienanalyse

What does Acer Therapeutics do?

Acer Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel drugs for rare and life-threatening diseases. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts. The history of Acer Therapeutics began with an innovative strategy for rediscovering already approved drugs for new therapeutic applications. The company utilizes a "repurposing" technology, in which already approved drugs are reevaluated and further developed for the treatment of rare diseases. Acer Therapeutics' business model includes a combination of in-house research activities, strategic partnerships, and acquisitions. The company follows a portfolio strategy with a focus on rare diseases to develop a diversified pipeline of innovative medications. The various divisions of Acer Therapeutics focus on different therapeutic areas. Currently, the company is focused on the development of drugs for the treatment of rare anemia, severe lymphocytic leukemia, and narcolepsy. Acer Therapeutics' flagship product is EDSIVO, a medication for the treatment of arterial hypertension, a rare and life-threatening condition characterized by elevated blood pressure in the arteries. EDSIVO is currently approved in the United States and is under review in Europe. The company plans to further develop EDSIVO for the treatment of other rare diseases. Another important product of Acer Therapeutics is ACER-001, a medication for the treatment of the rare metabolic disorder urea cycle disorders. ACER-001 is an oral formulation of sodium phenylbutyrate and is intended to help patients regulate ammonia metabolism and alleviate symptoms. In recent years, Acer Therapeutics has also entered into several strategic partnerships and acquisitions to expand and strengthen its pipeline of rare diseases. In 2019, the company acquired biopharmaceutical specialist Celipheon, thereby expanding its portfolio to include drugs for the treatment of anemia and leukemia. Another important partner of Acer Therapeutics is Ultragenyx Pharmaceutical, a biopharmaceutical company specializing in the development of therapies for rare and ultra-rare diseases. The two companies have entered into a licensing agreement for ACER-001, in which Ultragenyx has exclusive rights for the commercialization of the medication in North America and Europe. Overall, Acer Therapeutics' business model and portfolio strategy have made it a key player in the rare disease sector. Through partnerships and acquisitions, it has expanded its pipeline and focused its research on various therapeutic areas. The company is currently in a growth phase and has the potential to bring more groundbreaking medications for rare diseases to the market in the future. Acer Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Acer Therapeutics's Sales Figures

The sales figures of Acer Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Acer Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Acer Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Acer Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Acer Therapeutics stock

How much revenue did Acer Therapeutics generate this year?

Acer Therapeutics has achieved a revenue of 49.4 M USD this year.

How much was the turnover of the company Acer Therapeutics compared to the previous year?

The revenue of Acer Therapeutics has increased by 458.59% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Acer Therapeutics?

The revenue of Acer Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Acer Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Acer Therapeutics so important for investors?

The revenue of Acer Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Acer Therapeutics pay?

Over the past 12 months, Acer Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acer Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Acer Therapeutics?

The current dividend yield of Acer Therapeutics is .

When does Acer Therapeutics pay dividends?

Acer Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acer Therapeutics?

Acer Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Acer Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acer Therapeutics located?

Acer Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acer Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acer Therapeutics from 9/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/22/2024.

When did Acer Therapeutics pay the last dividend?

The last dividend was paid out on 9/22/2024.

What was the dividend of Acer Therapeutics in the year 2023?

In the year 2023, Acer Therapeutics distributed 0 USD as dividends.

In which currency does Acer Therapeutics pay out the dividend?

The dividends of Acer Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Acer Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Acer Therapeutics

Our stock analysis for Acer Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acer Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.